Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07190755Recruiting
Symptom tracking with a smartphone app for head and neck cancer
This trial uses a smartphone app to track your symptoms during radiation treatment for head and neck cancer. It aims to help your care team catch problems early and improve your quality of life.
RouenAges 18–75 - NCT07188077Recruiting
Study of immune changes in brain lymphoma
This trial looks at the immune system and metabolism of people with primary central nervous system lymphoma (a type of brain cancer) to find differences that might help with future treatments. It does not test a new drug, but collects samples and medical information.
Fuzhou, FujianAges 18–75 - NCT06718972Recruiting
Lung cancer with brain lining spread: real-world treatment study
This study looks at how people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord are treated in real-world clinics in China. If you have received treatment for this spread since 2018, you may be able to help doctors learn what works best.
Guangzhou, GuangdongAges Any age - NCT04184505RecruitingPhase 3
Testing stem cell transplant in higher-risk myelodysplastic syndrome
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
AlessandriaAges 18–70 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT07175480RecruitingPhase 2
Stopping treatment for kidney cancer based on PET/CT results
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Nanjing, JiangsuAges 18 years+ - NCT07180992Recruiting
Monocytes and CART cell response in multiple myeloma
This trial looks at how certain immune cells (monocytes) affect the success of CART cell therapy for multiple myeloma. It may help doctors improve treatment for future patients.
AmiensAges 18 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07182240Recruiting
Study of a new imaging method for skin cancer surgery
This study is testing a new imaging technology that helps surgeons see if all the cancer cells have been removed during Mohs surgery for basal cell carcinoma. It may help improve accuracy and reduce the need for additional surgeries.
Buffalo, New YorkAges 18 years+ - NCT07175077Recruiting
7T MRI scan to find tiny brain metastases in small-cell lung cancer
This trial uses a powerful 7T MRI scanner to detect very small brain metastases in people with small-cell lung cancer who choose not to get preventive brain radiation. The goal is to see if this advanced scan can find hidden spots in the brain that regular MRIs miss.
Columbia, MissouriAges 18 years+ - NCT07183384RecruitingPhase 1/Phase 2
Exosome therapy for blood vessel health after preeclampsia
This study tests whether exosomes from mesenchymal stem cells can help repair the blood vessels after preeclampsia. If you delivered within the last two weeks and had preeclampsia, you may qualify to take part.
Bandung, West JavaAges 18–50 - NCT07182682RecruitingPhase 3
Sunvozertinib after surgery for early-stage NSCLC with certain EGFR mutations
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
BeijingAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT07174908RecruitingPhase 3
New drug combo vs standard therapy for KRAS G12C lung cancer
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Beijing, Beijing MunicipalityAges 18–80 - NCT07174388Recruiting
Study comparing treatments for advanced lung cancer using medical records
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
Monterey, CaliforniaAges 18 years+ - NCT07175220RecruitingPhase 2
Study of SHR2554 tablets combined with other treatments for lung cancer
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
Guangzhou, GuangdongAges 18–75 - NCT05863234RecruitingPhase 1/Phase 2
Safety study for aggressive NK-cell leukemia patients
This early-phase study tests a new treatment approach for people with aggressive NK-cell leukemia, focusing mainly on safety. It may be offered to patients whose disease matches the study’s specific leukemia diagnosis rules.
Hiroshima, HiroshimaAges 18–70 - NCT06613490RecruitingEarly Phase 1
CAR NK cells for antibody syndrome and rheumatoid arthritis
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
Nanjing, JiangsuAges 18–70 - NCT06337474RecruitingEarly Phase 1
CD19 CAR NK cells for hard-to-treat immune thrombocytopenia
This study tests whether a new treatment using specially designed immune cells (CD19 CAR NK cells) can help people with immune thrombocytopenia (ITP) that has not improved with standard treatments. It aims to improve platelet counts and reduce bleeding risk.
Changzhou, JiangsuAges 18–65 - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07170995RecruitingPhase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Jinan, ShandongAges 18–75 - NCT07166757RecruitingPhase 1/Phase 2
Study of XS411 for early-onset Parkinson's disease
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07166445Recruiting
Using AI to read kidney cancer CT scans for better staging
This study uses a computer program (deep learning) to look at your kidney CT scan and tell if your cancer is more advanced (stage T3) or earlier (stage T1-T2). The goal is to help doctors plan the best treatment for you.
BeijingAges 18–85
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.